COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00606138
Recruitment Status : Completed
First Posted : February 1, 2008
Results First Posted : November 6, 2014
Last Update Posted : November 6, 2014
Genentech, Inc.
Information provided by (Responsible Party):
Rush University Medical Center

Brief Summary:
Diabetic neovascularization refers to a type of diabetic retinopathy which is worsening by the abnormal growth of blood vessels in the back of the eye, damaging the retina. The usual treatment is a type of laser, called panretinal photocoagulation. One drawback is that the amount of space within the eye for use of this treatment eventually has its limit, and should not be used too near the part of the retina used for detailed vision (the macula). In similar eye disorders, there are certain injectable medications called anti-VEGF treatments which can slow down or stop this abnormal blood vessel growth. This study sought to compare use of ranibizumab versus standard panretinal photocoagulation in treatment of diabetic neovascularization.

Condition or disease Intervention/treatment Phase
Proliferative Diabetic Retinopathy Drug: ranibizumab Procedure: Laser photocoagulation Phase 1 Phase 2

Detailed Description:
The purpose is to compare the efficacy of ranibizumab versus additional panretinal photocoagulation on diabetic neovascularization that is persistent despite previous treatment with panretinal photocoagulation. We hypothesize that ranibizumab intravitreal injections would induce neovascular regression in similar or better fashion than supplemental laser photocoagulation. Consented, enrolled subjects will either receive open-label intravitreal injections of 0.5-mg dose of ranibizumab or additional panretinal photocoagulation (up to 500 300-500 um laser spots) in a ratio of two-to-one (2:1) at the beginning of the study period. ETDRS best-corrected visual acuity, contrast sensitivity, and Optos color photography will be performed at enrollment, at weeks 1, 2, 3 and 4, and at months 2, 3, 4, 5 and 6. The subjects will undergo fluorescein angiography utilizing the Optomap FA (fluorescein angiography) system and optical coherence tomography (OCT) at enrollment, at weeks 2 and 4, and at months 2, 3, 4 and 6. The subjects will be followed for a 6-month period for stabilization, regression, or recurrence of neovascularization. In addition, patients will be evaluated for occurrence of macular edema.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigation of Ranibizumab for the Treatment of Persistent Diabetic Neovascularization as Assessed by Super Wide-Field Angiography (Optos)
Study Start Date : January 2008
Actual Primary Completion Date : October 2010
Actual Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: Anti-VEGF injection
Intravitreal injection of 0.5-mg dose of ranibizumab
Drug: ranibizumab
One 0.5 mg intravitreal injection
Other Name: Lucentis

Active Comparator: PRP Laser
Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
Procedure: Laser photocoagulation
panretinal photocoagulation (up to 500 300-500 um laser spots)

Primary Outcome Measures :
  1. The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) [ Time Frame: Week 4; Month 6 ]
    This is a measurement of how much change in neovascularization has occurred, using the Optomap FA readings to calculate the increase or decrease in surface area of the retina that is affected by neovascularization.

  2. The Mean Percentage Change of Macular Edema Measured by Retinal Thickness by OCT (Optical Coherence Tomography) [ Time Frame: Week 4; Month 6 ]
  3. Incidence and Severity of Ocular Adverse Events, as Identified by Ophthalmic Examination [ Time Frame: Month 6 ]
  4. Incidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ]

Secondary Outcome Measures :
  1. Mean Change in Best Corrected Visual Acuity (BCVA), as Assessed by the Number of Letters Read Correctly on the ETDRS Eye Chart at a Starting Test Distance of 4 Meters [ Time Frame: Week 4; Month 6 ]
  2. Percentage of Patients Gaining 3 or More Lines of Vision According to ETDRS Eye Chart Testing [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ]
  3. Occurrence Rate of Proliferative Diabetic Complications Including Vitreous Hemorrhage, Iris Neovascularization, and Tractional Retinal Detachment [ Time Frame: Month 6 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age 18 years or older

Patient related considerations:

  • Patients with Diabetes Mellitus (Type I or II) are eligible. HgA1c will be evaluated at the beginning of the study, but this value will have no significance in inclusion or exclusion.
  • Patients will not be pregnant at enrollment and must provide evidence of the use of two types of birth control while enrolled in the study.
  • Patients will have no known sensitivity to ranibizumab or other anti-VEGF injections.

Disease related considerations:

  • Patients will have diabetic neovascularization as seen on fluorescein angiography that was previously treated with full (at least 1200 laser burns) panretinal photocoagulation and that has persisted at least three months.
  • There will be no evidence of ocular inflammation at enrollment.
  • There is no restriction on patient's current medications or concomitant illnesses as long as there is no interference with patient follow-up.

Other considerations:

  • Patients may not be enrolled in another clinical study or observational trial.
  • There is no limitation on patient's institutional status as long as the patient is able to participate in follow-up.

Exclusion Criteria:

  • Pregnancy (positive pregnancy test)
  • Uncontrolled glaucoma on three medicines or more to control intraocular pressure
  • Prior enrollment in the study
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous medical investigation or trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00606138

Layout table for location information
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
Genentech, Inc.
Layout table for investigator information
Principal Investigator: Mathew W MacCumber, MD, PhD Rush University Medical Center
Layout table for additonal information
Responsible Party: Rush University Medical Center Identifier: NCT00606138    
Other Study ID Numbers: 06120402
First Posted: February 1, 2008    Key Record Dates
Results First Posted: November 6, 2014
Last Update Posted: November 6, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Retinopathy
Neovascularization, Pathologic
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Pathologic Processes
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents